A biotool is a molecule that has been discovered, characterized, sometimes further developed, up to the level of a (or several) publication(s) or a patent(s), and with valuable information on several key indicators such as target identity, high affinity/selectivity, functional effects in vitro, functional effects in vivo, compound availability, physicochemical data, Pharmacokinetic data etc...
| Nom de la sonde | Protéine cible | Structure |
|---|---|---|
| chalcone 4 | CXCL12 |
|
| ANA-12 | TrkB |
|
| bisacodyl | First described as cytotoxic to glioblastoma quiescent cells. Supposed to target WNK1 kinase pathway |
|
| PP-13 | Tubuline colchicine site |
|
| LPI 805 | NK2R tachykinin receptor |
|
| Liminib or Pyr1 | Lim Kinase |
|
| BDT001 | FLT3 |
|
| NMDI1 | NMD |
|
| ET-D5 | Protein Phosphatase 1 |
|
| Pyridocarbazole CK2-compound 18 | CK2 |
|
| C1 | Aurora kinases A/B |
|
| Retro-2.1 | intracellular pathogens |
|
| Daunorubicin | First identified as inhibiting MNBL1 and RNA (Muscleblind 1) |
|
| LIT-927 | CXCL12 ligand |
|
| GPN 136 | CCL22 |
|
| GPN 279 | CCL17 |
|
| cpd14 CCR5 ago | CCR5 |
|
| SRN 927 | CXCL12 |
|
| 2-amino-7-phenyldihydroquinazoline | unknown |
|
| M-030-E05 | E05 se fixe sur une protéine mitochondriale appelée apoptosis-inducing factor (AIF, 57kDa). |
|
| X55 | inhibition of CDA-deficient tumor cells |
|
| TB001 | TrkB |
|
| SR-FB-MPSBS018 | haspin |
|
| LIT-001 | Oxytocin receptor |
|
| tamoxifen | CDK5/p25 |
|
| meriolin 3 | Multitarget inhibitor of Cyclin-Dependent Kinases (CDKs) |
|
| indirubins: 6-bromoindirubin-3'-oxime (BIO) | GSK-3 (primary target) |
|
| DD264 | human DHODH |
|
| IPPA17-A04 or IPP/CNRS-A017 | human DHODH |
|
| A1B1C3_2 | glycerolipid synthase Toxoplasma gondii |
|
| A51B1C1_1 | Glycerolipids synthases |
|
| GAC50 | human DHODH |
|
| sr7575 | not known |
|
| MSK-1 inhibitor (4-(2-Chlorophenyl)-1H- benzo[d]imidazol-2-amine Hydrobromide) | MSK-1 (Mitogen- and Stress-Activated Kinase 1) |
|
| CRCM5484 | Bromodomain and extra-terminal (BET) bromodomains proteins with a 475-fold selectivity for the second bromodomain of the BRD3 protein (BRD3-BDII) over its first bromodomain (BRD3-BDI) |
|